LEP and Obesity: To investigate whether IL-6 impacts the circulating serum adiponectin and leptin levels in humans, adiponectin and leptin were determined in the serum from people with obesity infused with the IL-6 receptor antibody tocilizumab (n = 13) or a placebo (n = 9).